Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine: A placebo-controlled study

A. U. Buzdar*, L. Esparza, R. Natale, R. Cody, K. Calzone, A. B. Benson, T. Sheehan, W. Berry

*Corresponding author for this work

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

This investigation was designed with the objective of improving on currently available antiemetic regimens to counteract the disabling side effects of cancer chemotherapy. The combination of lorazepam, dexamethasone, and promethazine was compared with dexamethasone and promethazine without lorazepam in a double-blind crossover study. The initial study population consisted of 92 women (most with breast cancer) and 7 men; all received moderately or highly emetogenic chemotherapy. Complete data for both periods of therapy were available for 73 of these patients. Crossover analysis showed a highly significant effect of lorazepam in reducing the severity of nausea (p = .003); the severity of vomiting was also reduced, but less dramatically (p = .051). The frequency of all degrees of nausea and vomiting was less with lorazepam, but the difference was not statistically significant. It is concluded that lorazepam added to dexamethasone and promethazine provides an effective regimen for counteracting the emetic side effects of cancer chemotherapy.

Original languageEnglish (US)
Pages (from-to)417-421
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume17
Issue number5
DOIs
StatePublished - Jan 1 1994

Fingerprint

Promethazine
Lorazepam
Antiemetics
Dexamethasone
Placebos
Drug Therapy
Nausea
Vomiting
Emetics
Double-Blind Method
Cross-Over Studies
Neoplasms
Breast Neoplasms
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Buzdar, A. U. ; Esparza, L. ; Natale, R. ; Cody, R. ; Calzone, K. ; Benson, A. B. ; Sheehan, T. ; Berry, W. / Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine : A placebo-controlled study. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1994 ; Vol. 17, No. 5. pp. 417-421.
@article{67852ad6a3834b3baf1a5c3773c1fc78,
title = "Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine: A placebo-controlled study",
abstract = "This investigation was designed with the objective of improving on currently available antiemetic regimens to counteract the disabling side effects of cancer chemotherapy. The combination of lorazepam, dexamethasone, and promethazine was compared with dexamethasone and promethazine without lorazepam in a double-blind crossover study. The initial study population consisted of 92 women (most with breast cancer) and 7 men; all received moderately or highly emetogenic chemotherapy. Complete data for both periods of therapy were available for 73 of these patients. Crossover analysis showed a highly significant effect of lorazepam in reducing the severity of nausea (p = .003); the severity of vomiting was also reduced, but less dramatically (p = .051). The frequency of all degrees of nausea and vomiting was less with lorazepam, but the difference was not statistically significant. It is concluded that lorazepam added to dexamethasone and promethazine provides an effective regimen for counteracting the emetic side effects of cancer chemotherapy.",
author = "Buzdar, {A. U.} and L. Esparza and R. Natale and R. Cody and K. Calzone and Benson, {A. B.} and T. Sheehan and W. Berry",
year = "1994",
month = "1",
day = "1",
doi = "10.1097/00000421-199410000-00012",
language = "English (US)",
volume = "17",
pages = "417--421",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine : A placebo-controlled study. / Buzdar, A. U.; Esparza, L.; Natale, R.; Cody, R.; Calzone, K.; Benson, A. B.; Sheehan, T.; Berry, W.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 17, No. 5, 01.01.1994, p. 417-421.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine

T2 - A placebo-controlled study

AU - Buzdar, A. U.

AU - Esparza, L.

AU - Natale, R.

AU - Cody, R.

AU - Calzone, K.

AU - Benson, A. B.

AU - Sheehan, T.

AU - Berry, W.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - This investigation was designed with the objective of improving on currently available antiemetic regimens to counteract the disabling side effects of cancer chemotherapy. The combination of lorazepam, dexamethasone, and promethazine was compared with dexamethasone and promethazine without lorazepam in a double-blind crossover study. The initial study population consisted of 92 women (most with breast cancer) and 7 men; all received moderately or highly emetogenic chemotherapy. Complete data for both periods of therapy were available for 73 of these patients. Crossover analysis showed a highly significant effect of lorazepam in reducing the severity of nausea (p = .003); the severity of vomiting was also reduced, but less dramatically (p = .051). The frequency of all degrees of nausea and vomiting was less with lorazepam, but the difference was not statistically significant. It is concluded that lorazepam added to dexamethasone and promethazine provides an effective regimen for counteracting the emetic side effects of cancer chemotherapy.

AB - This investigation was designed with the objective of improving on currently available antiemetic regimens to counteract the disabling side effects of cancer chemotherapy. The combination of lorazepam, dexamethasone, and promethazine was compared with dexamethasone and promethazine without lorazepam in a double-blind crossover study. The initial study population consisted of 92 women (most with breast cancer) and 7 men; all received moderately or highly emetogenic chemotherapy. Complete data for both periods of therapy were available for 73 of these patients. Crossover analysis showed a highly significant effect of lorazepam in reducing the severity of nausea (p = .003); the severity of vomiting was also reduced, but less dramatically (p = .051). The frequency of all degrees of nausea and vomiting was less with lorazepam, but the difference was not statistically significant. It is concluded that lorazepam added to dexamethasone and promethazine provides an effective regimen for counteracting the emetic side effects of cancer chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0027941195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027941195&partnerID=8YFLogxK

U2 - 10.1097/00000421-199410000-00012

DO - 10.1097/00000421-199410000-00012

M3 - Article

C2 - 8092114

AN - SCOPUS:0027941195

VL - 17

SP - 417

EP - 421

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -